A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy — MANOEUVRE

Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial

Official title:
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Facioscapulohumeral Muscular Dystrophy (FSHD)
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral

Clinical Trial Details

NCT number	NCT05548556
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 7, 2023
Completion date	October 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239224` - Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy	Phase 1/Phase 2
Completed	`NCT02603562` - Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy	Phase 1/Phase 2
Active, not recruiting	`NCT05397470` - Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)	Phase 3
Active, not recruiting	`NCT04264442` - Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)	Phase 2
Completed	`NCT04003974` - Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)	Phase 2